GH and Childhood-onset Craniopharyngioma: When to Initiate GH Replacement Therapy?
An erratum to this article was published (J Clin Endocrinol Metab, 20 Feb 2024 ↗)
Authors' conclusion
No association was found between GHRT time delay after childhood-onset craniopharyngioma treatment and an increased risk of recurrence or tumor progression, suggesting GH replacement therapy can be initiated 6 months after last treatment for craniopharyngiomas.
Study context
- Population
- Childhood-onset craniopharyngioma patients with GH deficiency treated with recombinant human GH (rhGH), single centre
- Participants
- 27 / 44 / 29
- Exposure
- rhGH initiation ≥12 months vs <12 months (and 6–12 months) after craniopharyngioma treatment
- >12-monthn = 27reference
- <12-monthn = 44
- 6-12 monthn = 29
- Outcome
- Risk of tumor new event (progression of residual tumor or recurrence after complete resection) after primary treatment
Methodological detailsobservational, monocenter
- Observational
- Monocenter
Main finding
As reported in the abstract
Event-free survival · 2 and 5 years
| Group | Value | 5-year EFS |
|---|---|---|
| >12-month | 81.5% (CI 61.1–91.9) | 69.4% (95% CI, 47.9-83.4) |
| <12-month | 72.2% (CI 56.3–83.1) | 69.8% (95% CI, 53.8-81.2) |
| 6-12 month | 72.4% (CI 52.4–85.1) | 72.4% |
Value
>12-month81.5% (CI 61.1–91.9)
<12-month72.2% (CI 56.3–83.1)
6-12 month72.4% (CI 52.4–85.1)
5-year EFS
>12-month69.4% (95% CI, 47.9-83.4)
<12-month69.8% (95% CI, 53.8-81.2)
6-12 month72.4%
- Between <12-month and >12-month: P = 0.98 and P = .91 — EFS not different between groups
Observational data: associations, not effects.
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
GH and Childhood-onset Craniopharyngioma: When to Initiate GH Replacement Therapy? J Clin Endocrinol Metab. Published 16 February 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →